BiotechTube

Alirocumab 150 MG/ML [Praluent]

Phase 3UNKNOWN
0 watching 0 views this week📈 Rising
76
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Hemodialysis

Conditions

Hemodialysis, Peritoneal Dialysis, Hypercholesterolemia, Atherosclerotic Disease

Trial Timeline

May 1, 2018 → Dec 31, 2020

NCT ID
NCT03480568

About Alirocumab 150 MG/ML [Praluent]

Alirocumab 150 MG/ML [Praluent] is a phase 3 stage product being developed by Regeneron Pharmaceuticals for Hemodialysis. The current trial status is unknown. This product is registered under clinical trial identifier NCT03480568. Target conditions include Hemodialysis, Peritoneal Dialysis, Hypercholesterolemia.

Hype Score Breakdown

Clinical
27
Activity
18
Company
9
Novelty
9
Community
10

Clinical Trials (1)

NCT IDPhaseStatus
NCT03480568Phase 3UNKNOWN

Competing Products

20 competing products in Hemodialysis

See all competitors
ProductCompanyStageHype Score
R744 + R744 + rHuEPO + rHuEPO + R744 placebo + rHuEPO placeboChugai PharmaceuticalPhase 3
77
R744 + R744Chugai PharmaceuticalPhase 3
77
R744Chugai PharmaceuticalPhase 3
77
roxadustatAstellas PharmaPhase 3
77
ASP7991Astellas PharmaPhase 1
33
roxadustat + Darbepoetin alfaAstellas PharmaPhase 3
77
roxadustatAstellas PharmaPhase 3
77
ASP1585Astellas PharmaPhase 2
52
Kiklin capsulesAstellas PharmaPre-clinical
23
DoravirineMerckApproved
85
BPS804 + PlaceboNovartisPhase 2
52
PA21 + Sevelamer hydrochlorideKissei PharmaceuticalPhase 3
76
PA21 + PA21 + PA21 + PA21 + PlaceboKissei PharmaceuticalPhase 2
51
PA21Kissei PharmaceuticalPhase 3
76
PA21Kissei PharmaceuticalPhase 3
76
[¹⁴C]EtelcalcetideAmgenPhase 1
32
Epoetin HospiraPfizerPhase 3
76
Epoetin HospiraPfizerPhase 3
76
sodium thiosulfateSanofiPre-clinical
22
EnoxaparineSanofiApproved
84

Other Products from Regeneron Pharmaceuticals

DupilumabApproved
84
Intravitreal Aflibercept Injection 2mgApproved
84
Intravitreal aflibercept injection 2.0mgApproved
84
PozelimabApproved
84
DupilumabApproved
84